Pharmacokinetics of the investigational cephalosporin ceftriaxone were studied after 30-min intravenous infusions of three ascending single doses of 0.5, 1, and 2 g crossed over in 12 normal subjects. Serially collected plasma and urine samples were analyzed for ceftriaxone by high-performance liquid chromatography. Plasma concentration-time profiles were characterized by a linear two-compartment open model with the following respective mean (+standard deviation) parameters at 0.5-, 1-, and 2-g dose levels: elimination half-life, 6.5 + 0.7, 6.2 + 0.8, and 5.9 ± 0.7 h; apparent volume of distribution, 8.5 + 1.1, 9.0 + 1.1, and 10.1 ± 1.0 liters; and plasma clearance, 929 ± 150, 1,007 ± 130, and 1,190 ± 150 ml/h. The respective renal excretion parameters were as follows: renal clearance, 373 ± 60, 399 ± 50, and 533 + 128 ml/h; and percentage of dose excreted unchanged in the 48-h urine samples, 41 ± 8, 39 ± 5, and 43 + 10. The 6-h elimination halflife of ceftriaxone was 2-to 10-fold longer than those reported for marketed and other known investigational cephalosporins. The small dose-related increases in the apparent volume of distribution and clearance parameters can be explained by the concentration-dependent plasma protein binding of ceftriaxone in humans.
The impact of the small dose-dependent changes in the pharmacokinetics of ceftriaxone is anticipated to be of negligible clinical significance.
In recent years, chemical modification of the side chain of 7-aminocephalosporanic acid has resulted in several newer parenteral cephalosporins such as cefotaxime (4), cefoperazone (10) , moxalactam (12) , ceftizoxime (7) , and ceftriaxone (17) . These cephalosporins exhibit expanded antibacterial spectra, increased potency against gram-positive and gram-negative bacteria, and increased stability against various types of fl-lactamases (2, 6, 15, 19, 20, 24, 25) .
Preliminary human pharmacokinetic studies have indicated the following. (i) Ceftriaxone is bound to human plasma proteins, and the binding is concentration dependent; e.g., the free fraction of ceftriaxone in plasma (f4) increases from 3.7 to 16.7% over a plasma concentration range of 0.5 to 300 j.g/ml (21) . (ii) The elimination half-life of ceftriaxone (6.4 to 8.8 h) (16, 18, 21) is substantially longer than those reported for cefotaxime (0.9 to 1.5 h) (8, 9, 13, 22) , cefoperazone (1.7 to 2.4 h) (1, 3, 8) , moxalactam (2.7 to 2.85 h) (22, 23) , ceftizoxime (1.4 h) (M. Nakashima, H. Hashimoto, K. Suzuki, and K. Nishijima, Abstr. Intersci. Conf. Antimicrob. Agents Chemother. 19th, Boston, abstr. no. 555, 1979) as well as the several marketed cephalosporins (0.6 to 1.8 h) (14, 15) . (iii) The non-linearity observed for the single-dose pharmacokinetics of ceftriaxone can be explained by its concentration-dependent plasma protein binding (21) .
In the experiments described in this report, single-dose pharmacokinetics of ceftriaxone were further investigated after intravenous infusion (at a constant rate over 30 min) of three doses (0.5, 1, and 2 g) of the drug to 12 human volunteers. The findings of this study indicate that ceftriaxone exhibited dose-dependent pharmacokinetics, but the dose-dependent changes in the pharmacokinetic parameters (volume of distribution and plasma clearance) were small (<30%) Study design. All subjects received three single intravenous doses of disodium ceftriaxone, equivalent to 0.5, 1, and 2 g of the free, anhydrous acid. Each dose was administered after an overnight fast, which was continued for an additional 4 h after drug administration. All subjects received 0.5 g as their first dose, 1 g as their second dose, and 2 g as their third dose. In each instance, the drug was dissolved in 100 ml of normal saline and was administered intravenously (antecubital vein) by means of an infusion pump (IMED no. 927) at a constant rate over a 30-min period. The successive doses were separated by a minimum of 1 week. Each higher dose was given only after we had determined that the previous dose had been well tolerated.
Sample collection. Blood specimens were obtained at 0 (control), 10, 20, 30 Linearity and precision. Both plasma and urine assays were linear (i.e., a plot of peak height ratio versus concentration was adequately described by an equation of the form, y = mx + b) over a 2-to 300-[g/ ml concentration range. The interday precision of the method was, on the average, 4% or better over the same concentration range, with an assay recovery of 97%. The assay was reproducible as judged by the slope of the line, which ranged from 0.0128 to 0.0141 with a mean (+standard deviation) of 0.0136 (±3%) for the plasma assay and ranged from 0.0095 to 0.0114 with a mean (±standard deviation) of 0.0102 (±6%) for the urine assay.
Pharmacokinetic analysis. Plasma concentration-time curves were biphasic (see Fig. 1 ), and therefore a two-compartment open model with zero-order infusion and first-order elimination was selected to describe the pharmacokinetics of ceftriaxone. We fitted the plasma concentration-time data of individual subjects, using the NONLIN program (11) , to the following equation (5), which describes plasma concentration at any time (t), during the infusion and postinfusion periods: (1) where Cp represents plasma concentration; A and B represent the coefficients of the biexponential equation; a and ,B are the hybrid disposition rate constants representing the fast and slow disposition phases, respectively; and T varies with time, i.e., T = t while infusion is continuing, and when infusion ceases, T becomes a constant corresponding to the time infusion was stopped.
The area under the plasma concentration-time curve from time zero to infinity (AUC) was calculated by using the conventional trapezoidal and extrapolation methods.
The following apparent volume-of-distribution parameters were determined:
where Ro represents the zero-order infusion rate, V, 
RESULTS
Plasma concentration-time data. Average plasma concentrations of ceftriaxone after 30-min, constant-rate intravenous infusion of 0.5-, 1-, and 2-g doses of the drug are presented in Table 1 . As expected, maximum plasma concentrations were observed at the end of the 30-min infusion, with mean values of 82, 151, and 257 ,ug/ml after 0.5-, 1-, and 2-g doses, respectively.
The increase in the mean maximum-plasmaconcentration value at the 2-g dose level was 15 to 20% less than that predicted from the 0.5-and 1-g dose data when linear pharmacokinetics were assumed. Twelve hours after drug administration, significant plasma concentrations were observed after all three doses, and mean concentrations resulting from the 0.5-, 1-, and 2-g doses were 15 , 28, and 46,Lg/ml, respectively. Twentyfour hours after drug administration, mean plasma concentrations were 5, 9, and 15 ,tg/ml after the 0.5-, 1-, and 2-g doses, respectively.
The pharmacokinetic parameters estimated from the plasma concentration data are listed in Harmonic mean values.
Renal excretion. Average urinary concentrations of intact ceftriaxone after 0.5-, 1-, and 2-g doses are reported in Table 3 . The mean urine concentrations in the 0-to 2-h urine samples were 526 iLg/ml after the 0.5-g dose, 995 ,ug/ml after the 1-g dose, and 2,692 ,ug/ml after the 2-g dose. In the 24-to 48-h urine samples, the respective mean concentrations were 15, 32, and 40 iLg/ml. The cumulative renal excretion profiles (Table 4 ) of ceftriaxone indicated that the renal excretion profiles were similar after the 0.5-and 1-g intravenous doses. However, a significantly higher fraction of the dose was excreted unchanged in the 0-to 2-h interval after the 2-g dose than that observed after the 0.5-or 1-g dose (Table 4) . In 48 h, 41, 39, and 43% of the dose was excreted as intact ceftriaxone in the urine after 0.5-, 1-, and 2-g doses, respectively.
The renal clearances of the total drug were calculated for each urine collection interval (Table 5 0.5-, 1-, and 2-g doses at a constant rate over a 30-min period. The plasma concentration-time curves of ceftriaxone in the postinfusion phase were biphasic, with a relatively short distribution phase (overall mean distribution half-life, 0.17 h) followed by a slow elimination phase (overall mean elimination half-life, 6.1 h). Biexponential plasma concentration-time curves of ceftriaxone, with mean elimination half-lives ranging from 6.5 to 8.6 h, were previously reported (16, 18, 21) . In the present study, a small but statistically significant decrease in the elimination rate constant was observed; it increased from a mean value of 0.110/h at the 0.5-g dose to 0.113/h (2.7%) at the 1-gm dose to 0.119/h (8.2%) at the 2-g dose (Table 2) . However, in a previous study (21) , such a statistically significant dose-dependent decrease in the elimination rate constant was not observed, even with a 10-fold change in the dose (0.15 g to 1.50 g).
Significant dose-related increases were observed in the plasma clearance and volume of distribution; these findings are consistent with those of Stoeckel et al. (21) . Stoeckel et al. observed that a threefold increase in the dose (0.5 to 1.5 g) resulted in a 27% increase in plasma clearance (from 10.2 to 13.0 ml/min) and a 28% increase in the volume of distribution (from 6.7 to 8.6 liters). In the present study, the observed increase in plasma clearance (28% from 0.929 liter/h to 1.190 liter/h) was comparable, whereas (21) .
The renal clearance showed both dose-and time-related changes. It increased as the dose was increased during the first 8 h (Fig. 1) . After each intravenous dose, the renal clearance declined at each time interval measured during the first 8 h and then remained relatively constant over the subsequent time period (Fig. 1) . This decline in renal clearance from the 0-to 2-h interval to the 12-to 24-h interval was largest (63%) after administration of the 2-g dose and moderate (30 to 35%) after administration of the 0.5-and 1-g doses. These observations are consistent with the data of Stoeckel et al. (21) . In both of these studies, increased renal clearance at the highest dose did not increase the fraction of the dose excreted unchanged in the urine at that dose because of a similar increase in the nonrenal clearance of ceftriaxone. In 48 h, 41, 39, and 43% of the dose was excreted unchanged in the urine after the 0.5-, 1-, and 2-g doses, respectively. These values are similar to those (33 to 44%) reported previously from our laboratories (16) .
The renal excretion data indicate that a sub- Because of concentration-dependent plasma protein binding of ceftriaxone, the area under the total plasma concentration-time curve, as reported herein, is expected to show a less-thanproportional increase with an increase in the dose. However, area under the free (therapeutically active, unbound drug) plasma concentration-time curve is expected to be proportional to the dose. In a previous study (21) , this was substantiated, because the free plasma concentration-time curve increased proportionately from 10.1 to 106 ,g.h/ml over a 0.15-to 1.5-g dose range. Additionally, multiple dose studies (1 and 2 g every 12 h) (16) indicate that steadystate total plasma concentrations of ceftriaxone predicted from the single-dose data derived by assuming linear pharmacokinetics were overestimated by only 10 to 20%. Therefore, the impact of the nonlinear pharmacokinetics of ceftriaxone on its clinical usage is anticipated to be insignificant.
In conclusion, intravenous single-dose phar- macokinetics of ceftriaxone were investigated over a 0.5-to 2-g dose range. Ceftriaxone exhibited a relatively long elimination half-life (6.2 h) and a relatively small volume of distribution (9.1 liters) and plasma clearance (17.4 ml/min). Approximately 40% of the dose was excreted unchanged in the urine within 48 h after drug administration. The small dose-related changes in volume and clearance parameters were of negligible clinical significance. The 6-h elimination half-life of ceftriaxone suggests that a twicea-day or possibly once-a-day dosage regimen may be adequate for clinical use.
